1 citations
,
April 2006 in “International Journal of Oncology” Lysocellin helps stop cell damage from etoposide and may prevent hair loss.
March 2026 in “Korean Journal of Clinical Pharmacy” In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.
May 2022 in “The Journal of Clinical Pharmacology” Metformin reduces certain hormone levels in men with early-onset hair loss.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
October 2025 in “EMJ Dermatology” GLP-1RA therapy may increase the risk of hair loss.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
December 2015 in “Endocrinology and Metabolic Syndrome” January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly”
12 citations
,
December 2018 in “Clinical Ophthalmology” Latanoprostene bunod effectively lowers eye pressure and is better tolerated than other glaucoma medications.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.
1 citations
,
May 1992 in “Pharmacological Research” 39 citations
,
June 2019 in “Frontiers in Endocrinology” Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
15 citations
,
June 2023 in “Molecules” Agarose/fucoidan hydrogels may help treat diabetes by supporting pancreatic cell growth.
July 2013 in “Journal of clinical & experimental dermatology research” Bimatoprost can help treat hair loss.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
September 2025 in “Clinical and Experimental Rheumatology”
1 citations
,
June 2017 in “Skin” Apremilast may help treat lichen planopilaris and frontal fibrosing alopecia when other treatments fail.
1 citations
,
December 2024 in “Archives of Iranian Medicine” Tofacitinib may help treat Lichen Planopilaris, but more research is needed.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
10 citations
,
September 2015 in “Gynecological Endocrinology” Both treatments reduced excessive hair growth in PCOS, but there was no difference in weight, hair score, hormone levels, or insulin resistance.
2 citations
,
November 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
40 citations
,
April 2008 in “European journal of endocrinology” Metformin and rosiglitazone both improved insulin use and hormonal symptoms in women with PCOS.